Dr. David Andrews, Director of the Pre-Clinical Scientific Alliance, AstraZeneca, discusses the work of the Perturbation of Protein-Protein Interactions (PoPPI) program, a collaboration between AstraZeneca, the University of Leeds, University of Bristol, Northern Institute for Cancer Research and Domainex. Hear how the researchers working on this program are developing computational and chemical tools to design and synthesize new small molecule drugs that will target specific binding sites for selective inhibition of protein-protein interactions and how this approach may help develop new treatments for diseases, such as Leukemia.